CJC-1295 + Ipamorelin
Growth Hormone Releasing Peptide Stack
Dosage
10mg
Unit Size
1 Vial
// Add to Cart
10mg
$80.00
38 in stock
What is CJC-1295 + Ipamorelin?
CJC-1295 is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) — a 29-amino-acid peptide engineered to dramatically extend the half-life of natural GHRH from minutes to 7–8 days. By binding to albumin in the bloodstream via a Drug Affinity Complex, it produces sustained, pulsatile growth hormone release. When combined with Ipamorelin, a selective ghrelin mimetic, the stack creates synergistic GH release without the hormonal side effects of direct GH administration.
7–8 days
Half-life (DAC form)
2–3×
GH Baseline Increase
29 aa
Amino Acid Chain
Key Benefits
Muscle Growth
Stimulates IGF-1 production, driving protein synthesis and lean muscle tissue development.
Fat Loss
Elevated GH levels shift metabolism toward lipolysis — burning fat as the primary fuel source.
Recovery
Accelerates tissue repair and reduces downtime between training sessions through GH-mediated regeneration.
Anti-Aging
Restores youthful GH pulsatility, improving skin elasticity, cellular regeneration, and overall vitality.
Sleep Quality
Enhances slow-wave sleep — the phase where GH secretion and tissue repair peak naturally.
Bone Density
Sustained IGF-1 elevation supports increased bone mineral density and joint health over time.
How It Works
Injection & Albumin Binding
CJC-1295 (DAC form) is administered subcutaneously. The DAC modification causes it to bind strongly to serum albumin, dramatically extending its circulation time to 7–8 days.
GHRH Receptor Activation
Over days, CJC-1295 continuously stimulates GHRH receptors in the pituitary gland, triggering repeated, natural-style GH pulses rather than a single large spike.
GH & IGF-1 Release
The pituitary releases growth hormone in sustained pulses. The liver converts GH into IGF-1, the downstream mediator responsible for most anabolic and recovery effects.
Systemic Performance Effects
Elevated GH and IGF-1 cascade into muscle protein synthesis, lipolysis, collagen production, and enhanced sleep — producing the full spectrum of benefits.
Common Protocol (Research Reference)
1–2 mg
Dose per injection
1×/week
Frequency (DAC form)
8–12 wks
Typical cycle length
Research Use Notice
CJC-1295 + Ipamorelin is a research peptide not approved by the FDA for human use. This information is for educational purposes only. Always consult a qualified healthcare professional before considering any peptide protocol.